Vireo Growth to Buy Cannabist Assets Out of Restructuring

Vireo Growth has agreed to buy cannabis cultivation, manufacturing and retail operations from The Cannabist Company across five states for up to $35 million, pulling a batch of dispensaries and production sites out of a rival’s court-supervised wind-down and moving the buyer toward one of the largest retail networks in US cannabis.

The definitive purchase agreement, announced July 20, 2026, has Vireo’s subsidiary Vireo Health of Arcadia buying assets in Colorado, Illinois, Massachusetts, New Jersey and West Virginia. Colorado is the one market where Vireo already operates; the other four are new. In total, the deal would add up to 25 dispensaries — including eight in Colorado — plus one cultivation site and one production facility.

The headline number is a ceiling, not a fixed price. Vireo would pay up to $18.75 million in cash at closing and up to $16.25 million in seller notes — so the seller effectively finances close to half the consideration — with the final figure subject to downward adjustments for cash, debt, tax liabilities and working capital at each business. Closings are staged market by market through the rest of 2026 and into 2027, each one gated on state cannabis regulators signing off.

Why the assets are on the block

The Cannabist Company — the multistate operator formerly known as Columbia Care — is selling because it is being taken apart. In March 2026 the company began court-supervised restructuring in Ontario under Canada’s insolvency regime after missing an interest payment on its senior notes, then sought protection in the United States through a Chapter 15 case in Delaware — the mechanism that lets a US court recognize a foreign insolvency. A Delaware bankruptcy judge granted that recognition on May 9, 2026, clearing the way for a creditor-supervised sale of the company’s state-by-state assets.

The recognition was itself a notable moment for the industry. Plant-touching cannabis businesses have historically been shut out of US bankruptcy court because the trade remains federally illegal, and federal bankruptcy watchdogs have routinely moved to throw such cases out. The Cannabist structured around that wall: the entities that filed are Canadian holding companies that hold no licenses and touch no cannabis directly, while the licensed US operating subsidiaries stayed out of the filing. The federal government did not object, and the court let the case proceed.

For Vireo, the upshot is a motivated seller and a low price. The five-state deal is the largest remaining piece of a national retreat in which Cannabist has already sold its Virginia business for about $130 million and lined up buyers for its Ohio and Delaware operations at $47 million and $16.5 million, while exiting New York entirely. Against those figures, $35 million for 25 dispensaries and two production assets across five states is cheap — a discount that reflects the seller’s position more than the assets’ output.

What it means for Vireo

The purchase is the latest in a rapid buying run. Over the past year Vireo has struck deals for FLUENT in Florida and for PharmaCann and Schwazze dispensaries in Colorado, among others, and it recently entered Pennsylvania through a license deal. The Cannabist assets extend that pattern into four more states at once.

Vireo frames the result in superlatives: counting deals that have been announced but not yet closed, it says the transaction would lift its pro forma footprint to roughly 230 dispensaries across 15 states and give it the second-largest dispensary network in the country. That is a projection, not a current position. Vireo today operates in 10 states with more than 170 dispensaries; the 230-store, 15-state platform exists only if the Cannabist deal and its other pending acquisitions — including the C21 Investments purchase in Nevada — all clear their approvals.

CEO John Mazarakis called the deal part of a “disciplined and strategic approach to industry consolidation.” The framing is the company’s; the mechanism is a distressed competitor selling operations under court supervision to pay down debt.

What has to clear first

Nothing changes hands yet. Each market’s closing depends on Canadian court sign-off — a sale-approval and vesting order in the restructuring — plus cannabis regulatory approval in the state where the assets sit. Vireo’s board and a committee of Cannabist’s independent directors have both approved the deal, but regulators in five states have not, which is why the company expects closings to run into 2027.

The Colorado piece lands as Cannabist’s broader pullback from the state is already visible; the operator recently exited its Denver cultivation as the wind-down reached Colorado. Vireo has said further divestitures could follow once the deal closes, citing regulatory review and portfolio optimization. For now, what exists is a signed agreement and a court process — not 25 new stores under Vireo’s name.